PERSPECTIVE THERAPEUTICS, INC. Financials Perspective Therapeutics, Inc.
Equities
CATX
US46489V1044
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.58 USD | -1.25% |
|
+5.33% | +293.03% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 42.08 | 39.25 | 55.03 | 35.12 | 112.8 | 927.3 | - | - |
| Enterprise Value (EV) 1 | 42.08 | 39.25 | 55.03 | 35.12 | 112.8 | 927.3 | 927.3 | 927.3 |
| P/E ratio | -7.81 x | -9 x | -12.9 x | -4.94 x | -2.36 x | -17.6 x | -13.7 x | -10.5 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 5.75 x | 4.06 x | 5.47 x | 9.89 x | 78.7 x | - | - | - |
| EV / Revenue | 5.75 x | 4.06 x | 5.47 x | 9.89 x | 78.7 x | - | - | - |
| EV / EBITDA | -8,302,505 x | -13,682,309 x | -19,149,179 x | - | - | - | - | - |
| EV / FCF | - | - | - | - | -2.97 x | -17.8 x | -17.3 x | 10.5 x |
| FCF Yield | - | - | - | - | -33.7% | -5.62% | -5.77% | 9.49% |
| Price to Book | 5.45 x | 5.42 x | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 67,388 | 87,232 | 141,915 | 142,113 | 280,571 | 586,916 | - | - |
| Reference price 2 | 0.6244 | 0.4500 | 0.3878 | 0.2471 | 0.4020 | 1.580 | 1.580 | 1.580 |
| Announcement Date | 9/24/19 | 9/17/20 | 9/21/21 | 5/1/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 7.314 | 9.68 | 10.05 | 3.552 | 1.434 | - | - | - |
| EBITDA | -5.068 | -2.869 | -2.874 | - | - | - | - | - |
| EBIT 1 | -5.254 | -3.549 | -3.446 | - | -40.94 | -49.35 | -59 | -63.23 |
| Operating Margin | -71.83% | -36.66% | -34.28% | - | -2,855.02% | - | - | - |
| Earnings before Tax (EBT) 1 | -5.144 | -3.446 | -3.387 | - | -40.11 | -46.7 | -56.23 | -63.23 |
| Net income 1 | -5.155 | -3.457 | -3.39 | - | -46.51 | -48.05 | -56.23 | -63.23 |
| Net margin | -70.48% | -35.71% | -33.72% | - | -3,243.24% | - | - | - |
| EPS 2 | -0.0800 | -0.0500 | -0.0300 | -0.0500 | -0.1700 | -0.0900 | -0.1150 | -0.1500 |
| Free Cash Flow 1 | - | - | - | - | -37.98 | -52.09 | -53.54 | 87.96 |
| FCF margin | - | - | - | - | -2,648.88% | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 9/24/19 | 9/17/20 | 9/21/21 | 5/1/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.6 | 2.71 | 2.063 | 2.088 | 1.909 | -4.902 | - | - | - | - | - |
| EBITDA | -0.721 | -0.916 | - | - | - | - | - | - | - | - | - |
| EBIT | -0.766 | -1.093 | - | -11.37 | -10.53 | -7.806 | - | - | - | - | -14.75 |
| Operating Margin | -29.46% | -40.33% | - | -544.73% | -551.81% | 159.24% | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -0.745 | -1.061 | - | -11.11 | -10.36 | -7.773 | -10.7 | -10.8 | -10.93 | -11.66 | -14.74 |
| Net income 1 | -0.745 | -1.061 | - | -11.11 | -10.36 | -24.68 | -12.7 | -11.5 | -10.93 | -11.66 | -14.74 |
| Net margin | -28.65% | -39.15% | - | -531.9% | -542.48% | 503.37% | - | - | - | - | - |
| EPS 2 | -0.0100 | -0.0100 | - | -0.0400 | -0.0400 | -0.0900 | -0.0250 | -0.0250 | -0.0250 | -0.0250 | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 5/13/21 | 9/21/21 | 5/15/23 | 8/11/23 | 11/14/23 | 3/28/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | - | -38 | -52.1 | -53.5 | 88 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | 0.1100 | 0.0800 | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 0.44 | 0.27 | - | - | 1.07 | 9 | 1 | 1 |
| Capex / Sales | 6.07% | 2.82% | - | - | 74.76% | - | - | - |
| Announcement Date | 9/24/19 | 9/17/20 | 9/21/21 | 5/1/23 | 3/28/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.58
USD
Average target price
1.6
USD
Spread / Average Target
+1.27%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +293.03% | 927M | |
| -2.31% | 187B | |
| -3.20% | 106B | |
| -5.04% | 66.9B | |
| +0.20% | 49.45B | |
| +17.29% | 48B | |
| +4.06% | 40.84B | |
| +2.07% | 26.48B | |
| +2.36% | 26.25B | |
| +12.96% | 24.62B |
- Stock Market
- Equities
- CATX Stock
- Financials Perspective Therapeutics, Inc.
